In a recent retrospective analysis of a large contemporary cohort of 312 patients with metastatic breast cancer and LM treated with IT, the authors reported a median OS of 4.5 months and a 1‐year OS rate of 25% for the entire cohort, regardless of HER2 status.10 This evidence concerns the gene ERBB2 and lymphangioma.